

**REQUEST FOR NAMES, EMAILS, AND ADDRESSES OF SETTLEMENT CLASS MEMBERS**

STRATEGIC CLAIMS SERVICES  
600 N. JACKSON STREET, SUITE 205  
MEDIA, PA 19063

PHONE: (610) 565-9202      EMAIL: info@strategicclaims.net      FAX: (610) 565-7985

July 8, 2026

This letter is being sent to all entities whose names have been made available to us, or which we believe may know of potential Settlement Class Members.

**We request that you assist us in identifying any individuals/entities who fit the following description:**

ALL PERSONS AND ENTITIES THAT PURCHASED OR OTHERWISE ACQUIRED THE COMMON STOCK OF CYTODYN INC. ("CYTODYN") BETWEEN MARCH 27, 2020 AND MARCH 30, 2022.

Excluded from the Settlement Class are: Defendants, members of the Defendants' immediate families (as defined in 17 C.F.R. § 229.404, Instructions (1)(a)(iii) and (1)(b)(ii)), any person, firm, trust, corporation, officer, director, or other individual or entity in which any Defendant has a controlling interest, or which is related to or affiliated with any of the Defendants, and the legal representatives, agents, affiliates, heirs, successors-in-interest, or assigns of any such excluded party.

**The information below may assist you in finding the above requested information:**

<i>CytoDyn Securities Litigation Settlement</i> Case No. 3:21-cv-05190-BHS Claim Filing Deadline September 21, 2026 Exclusion Deadline: October 12, 2026 Objection Deadline: October 12, 2026 Notice To Appear Deadline: October 12, 2026 Settlement Hearing: November 2, 2026	<b>Security Identifiers:</b> CUSIP: 23283M101 ISIN: US23283M1018 Ticker Symbol: OTCQB: CYDY
--	--

**PER COURT ORDER, PLEASE RESPOND WITHIN 7 CALENDAR DAYS FROM THE DATE OF THIS NOTICE.**

Please comply in one of the following ways:

1. If you have no beneficial purchasers/owners, please advise us in writing; or
2. **Supply us with names, last known addresses, and email addresses (to the extent known)** of your beneficial purchasers/owners and we will do the emailing of the electronic Postcard Notice or emailing of the electronic link to the Notice of (I) Pendency of Class Action and Proposed Settlement; (II) Settlement Hearing; and (III) Motion for Attorneys' Fees and Litigation Expenses and the Proof of Claim and Release Form ("Notice and Claim Form") or mailing of the Postcard Notice. Please provide us this information electronically; or
3. Advise us of how many beneficial purchasers/owners you have, and we will supply you with ample postcards to do the mailing. After the receipt of the Postcard Notices, you have seven (7) calendar days to mail them; or
4. Request an electronic Postcard Notice or the link to the electronic Notice and Claim Form and email the link to each of your beneficial purchasers/owners within seven (7) calendar days after receipt thereof.

You can bill us for any reasonable expenses actually incurred and **not to exceed:**

- **\$0.03 per Postcard Notice emailed or electronic link to the Notice and Claim Form emailed, OR**
- **\$0.03 per name, address and email address** if you are providing us the records, OR
- **\$0.03 per name and address, including materials, plus postage at the current pre-sort rate used by the Claims Administrator** if you are requesting the Postcard Notices and performing the mailing.

Please use the following link to the Notice and Claim Form for emails: <https://cytodynsecuritiessettlement.com/wp-content/uploads/sites/22/2026/07/NOTICE1.pdf>

**All invoices must be received within 30 days of this letter.**

You are on record as having been notified of the legal matter. A copy of the Notice and Claim Form and other important case-related documents are available on the Settlement Website at [www.CytoDynSecuritiesSettlement.com](http://www.CytoDynSecuritiesSettlement.com). You can also request a copy via email at info@strategicclaims.net.

Thank you for your prompt response.

Sincerely,  
Claims Administrator  
*CytoDyn Securities Litigation Settlement*

**PLEASE NOTE - A COPY OF THE POSTCARD NOTICE IS ON THE REVERSE SIDE OF THIS LETTER**

CytoDyn Securities Litigation Settlement  
c/o Strategic Claims Services  
600 N Jackson St., Ste. 205  
Media, PA 19063

**COURT-ORDERED LEGAL NOTICE**

*Brian Joe Courter, et al. v. CytoDyn Inc., et al.*  
Case No. 3:21-cv-05190-BHS (W.D. Wash.)

Your legal rights may be affected by this securities class action. You may be eligible for a distribution from the Settlement. Please read this Postcard Notice carefully.

For more information, please visit  
[www.CytoDynSecuritiesSettlement.com](http://www.CytoDynSecuritiesSettlement.com),  
call toll free 1-866-274-4004,  
or send an email to [info@strategicclaims.net](mailto:info@strategicclaims.net)

CytoDyn Securities Litigation Settlement  
c/o Strategic Claims Services  
600 N. Jackson Street, Suite 205  
Media, PA 19063



**THIS POSTCARD NOTICE PROVIDES ONLY LIMITED INFORMATION ABOUT THE SETTLEMENT.  
PLEASE VISIT [WWW.CYTODYNSECURITIESSETTLEMENT.COM](http://WWW.CYTODYNSECURITIESSETTLEMENT.COM) FOR MORE INFORMATION.**

The parties in the securities class action *Brian Joe Courter, et al. v. CytoDyn Inc., et al.*, Case No. 3:21-cv-05190-BHS (W.D. Wash.) ("Action") have reached a proposed settlement ("Settlement") of claims asserted in the Action pursuant to Sections 10(b), 20(a) and 20A of the Securities Exchange Act of 1934 ("Exchange Act") against CytoDyn Inc. ("CytoDyn"), Nader Z. Pourhassan, Michael Mulholland, and Scott A. Kelly (collectively, "Defendants"). If approved, the Settlement will resolve the Action in which the Court-appointed Lead Plaintiff alleged that Defendants' public disclosures during the relevant time period misrepresented or omitted material facts regarding CytoDyn's drug Ieronlimab and its prospects for approval by the U.S. Food and Drug Administration for various applications. Lead Plaintiff further alleged that the price of CytoDyn common stock was artificially inflated as a result of Defendants' allegedly false and misleading statements, and declined when the alleged corrective disclosures were made. Defendants deny any liability or wrongdoing. You received this notice because you, or an investment account for which you serve as a custodian, may be a member of the following Settlement Class: All persons and entities that purchased or otherwise acquired the common stock of CytoDyn between March 27, 2020 and March 30, 2022, and were damaged thereby.

Pursuant to the Settlement, CytoDyn, on behalf of all Defendants, has agreed to provide to the Settlement Class total consideration of: (i) 49 million shares of CytoDyn common stock and (ii) \$500,000 in cash, which, after deducting Court-awarded fees and expenses, notice and administration costs, and taxes, will be allocated among Settlement Class Members who submit valid claims, in exchange for the Settlement and the release of all claims asserted in the Action and related claims. For additional information, please review the full Notice ("Notice") available at [www.CytoDynSecuritiesSettlement.com](http://www.CytoDynSecuritiesSettlement.com). If you are a Settlement Class Member, your pro rata share of the Settlement will depend on the number of valid claims submitted, and the number, size, and timing of your transactions in CytoDyn common stock during the Class Period. If all Settlement Class Members elect to participate in the Settlement, the estimated average recovery will be approximately \$0.04 per eligible share of CytoDyn common stock (based on the closing price of the stock on March 16, 2026) before deducting any fees and expenses. Your actual share of the Settlement will be determined pursuant to the proposed Plan of Allocation set forth in the Notice, or other plan ordered by the Court.

To qualify for a distribution from the Settlement, you must submit a valid Claim. The Claim Form can be found and submitted on the website, or you can request that one be mailed to you. Claims must be postmarked (if mailed), or submitted online, by September 21, 2026. If you do not want to be legally bound by any releases, judgments, or orders in the Action, you must exclude yourself from the Settlement Class by October 12, 2026. If you exclude yourself from the Settlement Class, you may be able to sue Defendants about the claims being resolved in the Action, but you cannot get a recovery from the Settlement. If you want to object to any aspect of the Settlement, you must file and serve an objection by October 12, 2026. The Notice provides instructions on how to submit a Claim, exclude yourself, or object, and you must comply with all of the instructions in the Notice.

The Court will hold a hearing on November 2, 2026 at 1:30 p.m., to consider, among other things, whether to approve the Settlement and a request by the lawyers representing the Settlement Class for up to 25% of the Settlement Fund in attorneys' fees, plus litigation expenses of no more than \$300,000 (which equals a cost of approximately \$0.01 per eligible share of CytoDyn common stock). You may attend the hearing and ask to be heard by the Court, but you do not have to. For more information, call 1-866-274-4004, send an email to [info@strategicclaims.net](mailto:info@strategicclaims.net) or visit [www.CytoDynSecuritiesSettlement.com](http://www.CytoDynSecuritiesSettlement.com).